Yiming Pharmaceutical: It is expected that the net profit will increase by 61.12%-122.08% compared to the same period in 2025.

Yiming Pharmaceuticals announced that it is expected to achieve a net profit of 74-102 million yuan in 2025, a year-on-year growth of 61.12% to 122.08%. During the reporting period, the company closely followed the direction of industry development and policy guidance, concentrated resources on the development of self-produced products, continuously improved the value and market share of self-produced products, achieved sales growth of the core self-owned product miglitol tablets, boosted overall profit, and laid the foundation for the company's long-term stable development; non-recurring gains and losses mainly came from government subsidies and compensation from Bosute performance commitment. It is estimated that the impact of non-recurring gains and losses on the company's net profit will be 43 million yuan.